Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Analysts
Ovid Therapeutics Inc. (NASDAQ:OVID – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. […]
Ovid Therapeutics Inc. (NASDAQ:OVID – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. […]
